Quinazoline analogs as receptor tyrosine kinase inhibitors
AssigneeArray BioPharma Inc.
InventorsEli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
Life of this patent
Estimating the term…
Abstract
The invention includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Claims8
A method of treating gliomas, cancer of the ovary, bladder cancer, cancer of the esophagus, cancer of the uterus, prostate cancer, kidney cancer, skin cancer, cancer of the pancreas, leukemias, or lymphomas comprising administering a therapeutically effective amount of a compound selected from the group consisting of:
A method of inhibiting the activity of ErbB2 comprising administering a compound selected from the group consisting of:
A method of treating diseases or medical conditions mediated by type I receptor tyrosine kinases which comprises administering to a warm-blooded animal an effective amount of a compound selected from the group consisting of:
Dependencies are inferred from the claim text.